Malene Brondberg, Nordic Nanovector interim CEO

Nor­we­gian biotech con­cludes 's­trate­gic' re­view with a re­verse merg­er

A lit­tle Nor­we­gian biotech an­nounced the end of its jour­ney Thurs­day in a re­verse merg­er, rough­ly three months af­ter an­nounc­ing it would es­sen­tial­ly sell it­self for parts.

Nordic Nanovec­tor will be swal­lowed by an­oth­er biotech based out of Nor­way, APIM Ther­a­peu­tics, the com­pa­nies said Thurs­day. When all is said and done, APIM share­hold­ers will own 76% of the com­bined com­pa­ny, which will un­veil a new name at a lat­er date, while Nordic Nanovec­tor share­hold­ers will have 24%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.